Prime Medicine (NASDAQ:PRME) Receives Buy Rating from Chardan Capital

Posted by Brenda Bartman on Sep 25th, 2026

Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $7.00 price objective on the stock. Chardan Capital’s price target indicates a potential upside of 141.38% from the company’s previous close.

Several other research analysts have also recently weighed in on the company. Wall Street Zen raised Prime Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Citigroup reiterated a “market outperform” rating on shares of Prime Medicine in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a research report on Monday, August 31st. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Prime Medicine in a research report on Monday, August 10th. Finally, TD Cowen reiterated a “buy” rating on shares of Prime Medicine in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Prime Medicine has an average rating of “Moderate Buy” and a consensus target price of $7.47.

Read Our Latest Stock Analysis on PRME

Prime Medicine Price Performance

Shares of NASDAQ:PRME traded down $0.17 during midday trading on Friday, hitting $2.90. 7,090,025 shares of the company’s stock were exchanged, compared to its average volume of 2,940,304. Prime Medicine has a 12 month low of $2.67 and a 12 month high of $6.94. The company has a market cap of $526.00 million, a PE ratio of -2.74 and a beta of 2.34. The stock has a 50 day moving average price of $3.25 and a 200-day moving average price of $3.37.

Prime Medicine (NASDAQ:PRME – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.24). The business had revenue of $1.15 million during the quarter, compared to the consensus estimate of $4.40 million. Prime Medicine had a negative return on equity of 188.27% and a negative net margin of 4,613.11%. On average, analysts anticipate that Prime Medicine will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Prime Medicine

Several large investors have recently added to or reduced their stakes in PRME. Royal Bank of Canada lifted its holdings in Prime Medicine by 89.3% during the first quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after purchasing an additional 4,365 shares during the last quarter. Glen Eagle Advisors LLC purchased a new position in shares of Prime Medicine in the fourth quarter worth about $35,000. Wealthfront Advisers LLC bought a new stake in shares of Prime Medicine in the first quarter valued at approximately $36,000. Kingsview Wealth Management LLC bought a new stake in shares of Prime Medicine in the second quarter valued at approximately $37,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Prime Medicine during the 1st quarter valued at approximately $41,000. Hedge funds and other institutional investors own 70.37% of the company’s stock.

About Prime Medicine

(Get Free Report)

Prime Medicine, Inc is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations.

Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient.